Tolemy Bio has secured €1.4 million in pre-seed funding, marking its first external capital raise, to develop its AI-powered cell biology research platform, Orbit. The funding, led by Norrsken Evolve with participation from Big Sur Ventures, JME Ventures, and Masia, will be used to expand data generation, machine learning, and engineering capabilities, and support early customer deployments. Tolemy Bio aims to integrate fragmented lab workflows into a single AI-native environment to optimize cell therapies and drug development.
